PepGen Inc. (PEPG) — Stock Valuation & Research

PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.

PEPG key statistics

Price$2.42
Market cap$167.74M
SectorHealthcare
IndustryBiotechnology
ExchangeNASDAQ
52-week range1.31-7.8
Beta2.02

Explore PEPG's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.